UK Orders 10.6 Million Doses of GSK/Biota Relenza To Cope With Tamiflu-resistant Flu

PERTH, Australia - Melbourne-based Biota Holdings announced recently that partner GlaxoSmithKline has been awarded a contract by the UK Department of Health for 10.6 million treatment courses of flu drug Relenza (zanamivir). Relenza was developed by Biota and is marketed by GSK